Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice | Zendy

Gracious R. Ross | Zendy; Aron H. Lichtman | Zendy; William L. Dewey | Zendy; Hamid I. Akbarali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice

Author(s) -

Gracious R. Ross,

Aron H. Lichtman,

William L. Dewey,

Hamid I. Akbarali

Publication year - 2012

Publication title -

pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.51

H-Index - 59

eISSN - 1423-0313

pISSN - 0031-7012

DOI - 10.1159/000339076

Subject(s) - inhibitory postsynaptic potential , cannabinoid receptor , cannabinoid , pharmacology , contractility , cannabinoid receptor type 2 , cannabinoid receptor agonists , receptor , biology , chemistry , neuroscience , endocrinology , biochemistry , antagonist

Cannabinoids inhibit intestinal motility via presynaptic cannabinoid receptor type I (CB1) in enteric neurons while cannabinoid receptor type II (CB2) receptors are located mainly in immune cells. The recently de-orphanized G-protein-coupled receptor, GPR55, has been proposed to be the 'third' cannabinoid receptor. Although gene expression of GPR55 is evident in the gut, functional evidence for GPR55 in the gut is unknown. In this study, we tested the hypothesis that GPR55 activation inhibits neurogenic contractions in the gut.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research